HCM / Takeda inks deal with Hutchmed for up to $1.1 billion

The mean of analysts' price targets for HUTCHMED (HCM) points to a 107.2% upside in the stock. While this highly sought-after metric has not proven re more_horizontal

Though artificial intelligence and machine learning have gotten their fair share of hype this year, not all of these companies are positioned to outpe more_horizontal

Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company more_horizontal

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SE more_horizontal

The consensus price target hints at a 103.8% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hard more_horizontal

The consensus price target hints at a 102.7% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hard more_horizontal

The mean of analysts' price targets for HUTCHMED (HCM) points to a 61.9% upside in the stock. While this highly sought-after metric has not proven rea more_horizontal

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SE more_horizontal